Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kordower, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease, Brain, 136, 2419, 10.1093/brain/awt192
Braak, 2003, Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol. Aging, 24, 197, 10.1016/S0197-4580(02)00065-9
Meissner, 2011, Priorities in Parkinson’s disease research, Nat. Rev. Drug Discov., 10, 377, 10.1038/nrd3430
Schapira, 2014, Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives, Lancet, 384, 545, 10.1016/S0140-6736(14)61010-2
Spillantini, 2000, The alpha-synucleinopathies: Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy, Ann. N Y Acad. Sci., 920, 16, 10.1111/j.1749-6632.2000.tb06900.x
Winner, 2011, In vivo demonstration that alpha-synuclein oligomers are toxic, Proc. Natl. Acad. Sci. USA, 108, 4194, 10.1073/pnas.1100976108
Chesselet, 2012, A progressive mouse model of Parkinson’s disease: the Thy1-aSyn (“Line 61”) mice, Neurotherapeutics, 9, 297, 10.1007/s13311-012-0104-2
Richter, 2014, Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons, Neurobiol. Dis., 69, 263, 10.1016/j.nbd.2014.05.012
Cabeza-Arvelaiz, 2011, Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons, Mol. Neurodegener., 6, 83, 10.1186/1750-1326-6-83
Whitehead, 2009, Knocking down barriers: advances in siRNA delivery, Nat. Rev. Drug Discov., 8, 129, 10.1038/nrd2742
Joshi, 2017, Destination brain: the past, present, and future of therapeutic gene delivery, J Neuroimmune Pharmacol., 12, 51, 10.1007/s11481-016-9724-3
Franich, 2008, AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease, Mol. Ther., 16, 947, 10.1038/mt.2008.50
Kim, 2017, RNA interference of human α-synuclein in mouse, Front. Neurol., 8, 13, 10.3389/fneur.2017.00013
Magen, 2014, Oligonucleotide-based therapy for neurodegenerative diseases, Brain Res., 1584, 116, 10.1016/j.brainres.2014.04.005
Rungta, 2013, Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain, Mol. Ther. Nucleic Acids, 2, e136, 10.1038/mtna.2013.65
Boussif, 1995, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine, Proc. Natl. Acad. Sci. USA, 92, 7297, 10.1073/pnas.92.16.7297
Neu, 2005, Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives, J. Gene Med., 7, 992, 10.1002/jgm.773
Aigner, 2007, Nonviral in vivo delivery of therapeutic small interfering RNAs, Curr. Opin. Mol. Ther., 9, 345
Akinc, 2005, Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis, J. Gene Med., 7, 657, 10.1002/jgm.696
Höbel, 2010, Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab, J. Gene Med., 12, 287, 10.1002/jgm.1431
Ibrahim, 2011, MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma, Cancer Res., 71, 5214, 10.1158/0008-5472.CAN-10-4645
Weirauch, 2013, Polymer-based delivery of RNA-based therapeutics in ovarian cancer, Methods Mol. Biol., 1049, 443, 10.1007/978-1-62703-547-7_34
Werth, 2006, A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes, J Control Release., 112, 257, 10.1016/j.jconrel.2006.02.009
Chesselet, 2011, Modelling of Parkinson’s disease in mice, Lancet Neurol., 10, 1108, 10.1016/S1474-4422(11)70227-7
Gerstenberger, 2016, The novel adaptive rotating beam test unmasks sensorimotor impairments in a transgenic mouse model of Parkinson’s disease, Behav. Brain Res., 304, 102, 10.1016/j.bbr.2016.02.017
Malek, 2008, PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy, J. Drug Target., 16, 124, 10.1080/10611860701849058
DiFiglia, 2007, Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits, Proc. Natl. Acad. Sci. USA, 104, 17204, 10.1073/pnas.0708285104
McCormack, 2010, Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra, PLoS ONE, 5, e12122, 10.1371/journal.pone.0012122
Gorbatyuk, 2010, In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration, Mol. Ther., 18, 1450, 10.1038/mt.2010.115
Khodr, 2014, Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects, Brain Res., 1550, 47, 10.1016/j.brainres.2014.01.010
Khodr, 2011, An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson’s disease, but displays toxicity in dopamine neurons, Brain Res., 1395, 94, 10.1016/j.brainres.2011.04.036
Schäfer, 2010, Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery, Biomaterials, 31, 6892, 10.1016/j.biomaterials.2010.05.043
de Fougerolles, 2007, Interfering with disease: a progress report on siRNA-based therapeutics, Nat. Rev. Drug Discov., 6, 443, 10.1038/nrd2310
Park, 2006, Current status of polymeric gene delivery systems, Adv. Drug Deliv. Rev., 58, 467, 10.1016/j.addr.2006.03.007
Kwon, 2010, Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone, Biomaterials, 31, 2417, 10.1016/j.biomaterials.2009.11.086
Joris, 2013, Assessing nanoparticle toxicity in cell-based assays: influence of cell culture parameters and optimized models for bridging the in vitro-in vivo gap, Chem. Soc. Rev., 42, 8339, 10.1039/c3cs60145e
Wang, 2008, Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression, J. Biol. Chem., 283, 15845, 10.1074/jbc.M800834200
Ewe, 2017, Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model, Drug Deliv. Transl. Res., 7, 206, 10.1007/s13346-016-0306-y
Merz, 2017, Tumor tissue slice cultures as a platform for analyzing tissue-penetration and biological activities of nanoparticles, Eur. J. Pharm. Biopharm., 112, 45, 10.1016/j.ejpb.2016.11.013
Devine, 2011, Parkinson’s disease and α-synuclein expression, Mov. Disord., 26, 2160, 10.1002/mds.23948
Simón-Sánchez, 2009, Genome-wide association study reveals genetic risk underlying Parkinson’s disease, Nat. Genet., 41, 1308, 10.1038/ng.487
Satake, 2009, Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease, Nat. Genet., 41, 1303, 10.1038/ng.485
Edwards, 2010, Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease, Ann. Hum. Genet., 74, 97, 10.1111/j.1469-1809.2009.00560.x
Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease, Nat. Genet., 46, 989, 10.1038/ng.3043
Del Tredici, 2012, Lewy pathology and neurodegeneration in premotor Parkinson’s disease, Mov. Disord., 27, 597, 10.1002/mds.24921
Braak, 2006, Cognitive decline correlates with neuropathological stage in Parkinson’s disease, J. Neurol. Sci., 248, 255, 10.1016/j.jns.2006.05.011
Richter, 2014, A GCase chaperone improves motor function in a mouse model of synucleinopathy, Neurotherapeutics, 11, 840, 10.1007/s13311-014-0294-x
Fleming, 2011, A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions, Mol. Cell. Neurosci., 46, 597, 10.1016/j.mcn.2010.12.011
Richter, 2017, A molecular tweezer ameliorates motor deficits in mice overexpressing α-synuclein, Neurotherapeutics, 10.1007/s13311-017-0544-9
Tan, 2005, Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat, Gene Ther., 12, 59, 10.1038/sj.gt.3302376
Bartlett, 2006, Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging, Nucleic Acids Res., 34, 322, 10.1093/nar/gkj439
Ewe, 2017, Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo, Nanomedicine (Lond.), 13, 209, 10.1016/j.nano.2016.08.005
Cooper, 2014, Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice, Mov. Disord., 29, 1476, 10.1002/mds.25978
Javed, 2016, Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson’s disease and other brain disorders, Mol. Ther., 24, 746, 10.1038/mt.2015.232
Cardo, 2013, Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls, J. Neurol., 260, 1420
Wong, 2012, miRNAs and their putative roles in the development and progression of Parkinson’s disease, Front. Genet., 3, 315
Goodall, 2013, Neuronal dark matter: the emerging role of microRNAs in neurodegeneration, Front. Cell. Neurosci., 7, 178, 10.3389/fncel.2013.00178
Höbel, 2013, Polyethylenimines for siRNA and miRNA delivery in vivo, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 5, 484, 10.1002/wnan.1228
Morris, 2015, Arginine-rich polyplexes for gene delivery to neuronal cells, Biomaterials, 60, 151, 10.1016/j.biomaterials.2015.04.052
Ko, 2009, Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting, J Control Release., 133, 230, 10.1016/j.jconrel.2008.10.013
Rockenstein, 2002, Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters, J. Neurosci. Res., 68, 568, 10.1002/jnr.10231
Richter, 2008, Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice, Brain Res., 1188, 148, 10.1016/j.brainres.2007.09.083
Paxinos, 2012